Mounjaro adds to your patient pathway — it doesn't replace it
January 2026's TGA approval of tirzepatide for moderate-to-severe OSA created Australia's first pharmacological OSA option. It doesn't replace polysomnography, CPAP titration, or specialist review — it creates a new cohort that needs all three on a different timeline.
Why this matters now
SURMOUNT-OSA demonstrated up to a 63% reduction in apnoea-hypopnoea index on tirzepatide. AHI improvement is individual, not linear with weight loss. Repeat polysomnography is the only valid way to retitrate — and your practice is where that happens.
The numbers
−63%
max AHI reduction on tirzepatide
SURMOUNT-OSA
Jan 2026
TGA OSA approval
TGA
1st
pharmacological OSA treatment in AU
TGA Jan 2026
Data view
The numbers behind the pitch
SURMOUNT-OSA — AHI reduction on tirzepatide (non-CPAP cohort)
Source: NEJM, June 2024 — SURMOUNT-OSA Phase 3
−62.8% AHI
Two independent double-blind RCTs across 58 sites in 9 countries. Best-case efficacy estimand, non-CPAP cohort, highest dose.
Why your referral pattern changed in January 2026
Source: TGA Product Information, January 2026
Jun 2024
SURMOUNT-OSA published in NEJM
Up to 63% reduction in AHI demonstrated — basis for regulatory submission.
Jan 2026
TGA approves Mounjaro for OSA
First pharmacological treatment for moderate-to-severe OSA in Australia.
From Jan 2026
New monitoring pathway
Patients losing weight on Mounjaro need repeat polysomnography to retitrate CPAP.
Clinical context
Mounjaro is additive, not displacing
Tirzepatide (Mounjaro) is now TGA-approved for moderate-to-severe OSA — Australia's first pharmacological sleep apnoea treatment. SURMOUNT-OSA demonstrated up to a 63% reduction in apnoea-hypopnoea index. None of that removes the need for polysomnography, formal CPAP titration, or specialist review — the medication creates a new patient cohort that needs every one of those services on a shifted timeline.
The clinical risk if no one monitors this
Patients are reading press coverage of SURMOUNT-OSA and unilaterally reducing or discontinuing CPAP. That carries real risk — AHI changes are individual and don't move with body weight in a linear way. Polysomnography is the only valid way to titrate. Your practice is the safety net.
A new and growing cohort
The intersection of obesity, GLP-1 therapy, and OSA is a clinically distinct cohort. Most sleep medicine clinics in Australia aren't yet listed on a directory where these patients (or their referring GPs) can find them. The directory closes that loop.
Evidence base
What the literature says, in one place
TGA approved tirzepatide for moderate-to-severe OSA in January 2026 — first pharmacological OSA treatment in Australia.
TGA, Jan 2026
SURMOUNT-OSA Phase 3: up to 63% reduction in apnoea-hypopnoea index with tirzepatide.
SURMOUNT-OSA trial
Patients should not reduce CPAP unilaterally — repeat polysomnography is the only valid titration method.
What your patients are searching
'Mounjaro sleep apnoea' is a Breakout search query in Australia with growing month-on-month volume. Patients and their GPs are searching — most sleep clinics in Australia aren't listed.
What a free profile gets you, as a sleep clinic
Be discoverable for the new Mounjaro OSA pathway.
Free profile shows polysomnography availability, MBS rebate status, and turnaround.
Direct routing from GP and dietitian referrer searches.
Built for clinicians, not marketers
We're an Australian-built directory focused on GLP-1 monitoring pathways. No booking fees, no commission, no upsells that gate basic functionality.
Free profile
SEO-optimised profile page that ranks in Google for your suburb + service.
Patient enquiry inbox
Enquiries from patients land in one simple inbox. Respond on your terms.
Demand analytics
See how many patients searched your suburb, viewed your profile, and called.
Verified badge
Once we verify credentials, you get priority placement and a Verified marker.
Claim your free profile in under 5 minutes
No credit card. No lock-in. Visible to patients in your suburb the moment you publish.